Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMS80DF)

Drug Name
ALDISIN Drug Info
Synonyms
72908-87-3; Aldisin; Aldisine; 6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione; 6,7-Dihydro-1H,5H-pyrrolo[2,3-c]azepine-4,8-dione; CHEMBL357047; AK134979; Pyrrolo[2,3-c]azepine-4,8(1H,5H)-dione, 6,7-dihydro-; Pyrrolo(2,3-c)azepine-4,8(1H,5H)-dione, 6,7-dihydro-; AC1MJ57G; SCHEMBL7844916; 6,7-dihydro-Pyrrolo[2,3-c]azepine-4,8(1H,5H)-dione; CTK5D7039; KS-00000FCK; DTXSID40223211; Pyrrolo[2,3-c]azepine-4,8(1H,5H)-dione,6,7-dihydro-; AAPGLCCSVSGLFH-UHFFFAOYSA-N; MolPort-000-003-213; ZINC13310235; BDBM50108777; FCH858612
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
3085877
CAS Number
CAS 72908-87-3
TTD Drug ID
DMS80DF

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting ERK activator kinase 1 (MEK1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Selumetinib DMC7W6R Neurofibromatosis type 1 LD2D.10 Phase 3 [2]
Diamidothiazole derivative 1 DM02V5Q N. A. N. A. Patented [3]
Pyridic ketone derivative 1 DM3GU7K N. A. N. A. Patented [4]
RDEA-436 DM0ILRU Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 1 [5]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB Discovery agent N.A. Investigative [6]
DEBROMOHYMENIALDISINE DMDLER8 Discovery agent N.A. Investigative [1]
REVERSINE DMWDNOK Discovery agent N.A. Investigative [7]
OROIDIN DMA2DQT Discovery agent N.A. Investigative [1]
PD98059 DMZC90M Cardiac arrest MC82 Investigative [8]
4,5-Dibromo-1H-pyrrole-2-carboxylic acid amide DMDM9UV Discovery agent N.A. Investigative [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
ERK activator kinase 1 (MEK1) TTIDAPM MP2K1_HUMAN Inhibitor [1]

References

1 Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1). J Med Chem. 2002 Jan 17;45(2):529-32.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
4 MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906.
5 Clinical pipeline report, company report or official report of MedKoo Biosciences.
6 Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
7 Reversine increases the plasticity of lineage-committed mammalian cells. Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10482-7.
8 The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis. Melanoma Res. 2001 Feb;11(1):11-9.